COPENHAGEN, Sept 12 (Askume) – Bavarian Nordic AG (BAVA.CO) said on Thursday it could supply 13 million doses of its Mpox vaccine by the end of 2025, up from a previous forecast of 10 million .
The Danish biotech said it has also identified measures that could increase supply to 50 million doses over the next 12-18 months, subject to regulatory approval and market demand.
Rolf Sass Sorensen, head of investor relations for the state of Bavaria, said: “It depends first of all on demand. If there is demand and the other conditions are in place, we have the opportunity to add another 50 million doses.”
The World Health Organisation declared ampox a global health emergency last month, but efforts to stop the spread of the disease have been hampered by a shortage of vaccines .
Sorensen said supply also depends on collaboration with partners on relocating manufacturing to Africa and elsewhere, as well as ongoing discussions about adopting other more productive methods and technologies.
“This can help you fill up and finish,” Sorensen said.
Bavaria said some existing Mpox vaccine orders based on contracts with the US government will be postponed from 2024 to 2025 to meet other market needs.
The Democratic Republic of Congo, the epicenter of the latest MPOX outbreak, received its first shipment of MPOX vaccines last week .
